Non-Squamous Non-Small Cell Lung Cancer
Conditions
Brief summary
This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer. In Part 1, patients will receive 4 cycles of treatment with Avastin (7.5mg/kg iv) plus cisplatin (75mg/m2 iv) plus pemetrexed (500mg/m2 iv) on day 1 of each 3-week cycle. In Part 2, patients responding to treatment will be randomized to receive further treatment cycles of Avastin (7.5mg/kg iv every 3 weeks) with or without pemetrexed (500mg/m2 iv every 3 weeks). Anticipated time on study treatment is until disease progression. Target sample size is \<500 individuals.
Interventions
DRUGbevacizumab [Avastin]
7.5mg/kg iv on day 1 of each 3-week cycle
DRUGcisplatin
75mg/m2 iv on day 1 of each 3-week cycle
DRUGpemetrexed
500mg/m2 iv on day 1 of each 3-week cycle
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adults \>/=18 years of age * inoperable, locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) * at least 1 measurable lesion meeting RECIST criteria * ECOG performance status 0-2 * adequate hematological, liver and renal function
Exclusion criteria
* prior chemotherapy or treatment with another systemic anti-cancer agent * malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS * evidence of tumor invading major blood vessels * current or recent use of aspirin (\>325mg/day) or full-dose anticoagulants or thrombolytic agents for therapeutic purposes * history of haemoptysis \>/=grade 2 * clinically significant cardiovascular disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival During Maintenance Treatment Phase | Up to 21 months | Progression free survival (PFS) is defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) , or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Progression is defined using (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions and increase of at least 5 mm in the sum of diameters of target lesions.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best Overall Response Rate During Maintenance Treatment Phase | Up to 21 months | The best overall response rate (BORR) is defined as the percentage of participants having achieved confirmed Complete Response (CR) and Partial Response (PR) as the best overall response. CR was defined as complete disappearance of all target lesions and non-target disease. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. Stable disease (SD) is defined as steady state of disease with neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter. |
| Duration of Response During Maintenance Treatment Phase | Up to 21 months | Duration of response is defined as the time in months from the initial start of response PR or better to the earlier of documented PD or death due to any cause. Participants who had neither progressed nor died at the date of clinical cutoff, who withdrew from the study, were lost to follow-up, or were without documented disease progression were censored at the date of the last available tumor assessment. The analysis was based on all participants with measurable disease at baseline who achieved response.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter. |
| Duration of Disease Control During Maintenance Treatment Phase | Up to 21 months | Duration of disease control is defined as the time in months from randomization to the earlier of documented PD or death due to any cause. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter. |
| Overall Survival During Maintenance Treatment Phase | Up to 21 months | Overall survival (OS) is assessed from the date of first induction treatment until the date of death. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter. |
| Number of Participants With Marked Laboratory Abnormalities | Up to 21 months | Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from Baseline. The reference range for Platelets was 100-550 (10\^9/L), for White blood cells (WBC) was 3.0-18.0 (10\^9/L), for Lymphocytes was 0.70-7.60 (10\^9/L), and Neutrophil 1.50-9.25 (10\^9/L ). |
| Quality of Life | Up to 21 months | European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Cancer 30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Lung Cancer 13 \[EORTC QLQ-LC13\]consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity. QOL was assessed using Pre-Induction Baseline (Pre-ind BL), Maintenance (MTC), End of study (EOS) cycles. |
| Incidence of Adverse Events and Serious Adverse Event | Up to 21 months | An adverse events (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution. |
Countries
France, Germany, Greece, Italy, Netherlands, Russia, South Korea, Spain, Sweden, Switzerland, Turkey (Türkiye), United Arab Emirates
Participant flow
Recruitment details
A total of 414 participants were screened out of which 38 participants were excluded for not meeting the eligibility criteria, declining to participate, or for other reasons. A total of 376 participants were recruited over an 18-month period across 81 centers in 11 countries from 17 August 2009 to 3 May 2011.
Pre-assignment details
Of the 376 participants enrolled in this study, 3 participants did not start induction phase treatment.
Participants by arm
| Arm | Count |
|---|---|
| Bevacizumab Maintenance Trt Arm A Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. The first cycle of maintenance therapy had to be administered a maximum of 4 weeks after the fourth cycle of induction therapy. | 125 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B Bevacizumab 7.5 mg/kg + pemetrexed 500 mg/m\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Pemetrexed-treated participants received standard supplementation with folic acid orally (350 to 1000 microgram \[mcg\] daily), vitamin B12 intramuscularly (1000 mcg every 3 cycles), and dexamethasone prophylaxis orally (4 mg twice a day) on Days -1, 1, and 2 of each cycle. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy. | 128 |
| Total | 253 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Induction Treatment Phase | Death | 77 | 0 | 0 |
| Induction Treatment Phase | Didn't meet maintenance phase criteria | 27 | 0 | 0 |
| Induction Treatment Phase | Other Reason | 5 | 0 | 0 |
| Induction Treatment Phase | Physician Decision | 2 | 0 | 0 |
| Induction Treatment Phase | Protocol Violation | 1 | 0 | 0 |
| Induction Treatment Phase | Withdrawal by Subject | 11 | 0 | 0 |
| Maintenance Treatment Phase | Death | 0 | 42 | 34 |
| Maintenance Treatment Phase | Investigators decision | 0 | 2 | 0 |
| Maintenance Treatment Phase | Other reason | 0 | 1 | 3 |
| Maintenance Treatment Phase | Withdrawal by Subject | 0 | 3 | 8 |
Baseline characteristics
| Characteristic | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B | Total |
|---|---|---|---|
| Age, Continuous | 59.5 years STANDARD_DEVIATION 8.25 | 59.3 years STANDARD_DEVIATION 8.86 | 59.4 years STANDARD_DEVIATION 8.55 |
| Sex: Female, Male Female | 55 Participants | 54 Participants | 109 Participants |
| Sex: Female, Male Male | 70 Participants | 74 Participants | 144 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 105 / 128 | 115 / 120 | 120 / 125 |
| serious Total, serious adverse events | 70 / 128 | 26 / 120 | 42 / 125 |
Outcome results
Primary
Progression Free Survival During Maintenance Treatment Phase
Progression free survival (PFS) is defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) , or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Progression is defined using (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions and increase of at least 5 mm in the sum of diameters of target lesions.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Population: The ITT population included all the participants that were randomized.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Bevacizumab Maintenance Trt Arm A | Progression Free Survival During Maintenance Treatment Phase | 6.6 Months |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Progression Free Survival During Maintenance Treatment Phase | 10.2 Months |
p-value: <0.00195% CI: [0.37, 0.69]Log Rank
Secondary
Best Overall Response Rate During Maintenance Treatment Phase
The best overall response rate (BORR) is defined as the percentage of participants having achieved confirmed Complete Response (CR) and Partial Response (PR) as the best overall response. CR was defined as complete disappearance of all target lesions and non-target disease. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. Stable disease (SD) is defined as steady state of disease with neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Population: The ITT population which included all the participants that were randomized.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bevacizumab Maintenance Trt Arm A | Best Overall Response Rate During Maintenance Treatment Phase | Partial response (PR) | 50 percentage of participants |
| Bevacizumab Maintenance Trt Arm A | Best Overall Response Rate During Maintenance Treatment Phase | Stable disease (SD) | 50 percentage of participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Best Overall Response Rate During Maintenance Treatment Phase | Partial response (PR) | 55.5 percentage of participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Best Overall Response Rate During Maintenance Treatment Phase | Stable disease (SD) | 44.5 percentage of participants |
Secondary
Duration of Disease Control During Maintenance Treatment Phase
Duration of disease control is defined as the time in months from randomization to the earlier of documented PD or death due to any cause. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Population: The ITT population included all the participants that were randomized.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Bevacizumab Maintenance Trt Arm A | Duration of Disease Control During Maintenance Treatment Phase | 4.9 Months |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Duration of Disease Control During Maintenance Treatment Phase | 7.8 Months |
p-value: <0.00195% CI: [0.38, 0.7]Log Rank
Secondary
Duration of Response During Maintenance Treatment Phase
Duration of response is defined as the time in months from the initial start of response PR or better to the earlier of documented PD or death due to any cause. Participants who had neither progressed nor died at the date of clinical cutoff, who withdrew from the study, were lost to follow-up, or were without documented disease progression were censored at the date of the last available tumor assessment. The analysis was based on all participants with measurable disease at baseline who achieved response.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Population: The ITT population included all the participants that were randomized.Participants available at particular time point for assessment were included in the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Bevacizumab Maintenance Trt Arm A | Duration of Response During Maintenance Treatment Phase | 5.7 Months |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Duration of Response During Maintenance Treatment Phase | 9.2 Months |
p-value: 0.00695% CI: [0.34, 0.84]Log Rank
Secondary
Incidence of Adverse Events and Serious Adverse Event
An adverse events (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution.
Time frame: Up to 21 months
Population: The safety population comprised of all participants who received at least one dose of study medication. Participants who received induction treatment and were not randomised to maintenance treatment are also included in analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bevacizumab Maintenance Trt Arm A | Incidence of Adverse Events and Serious Adverse Event | AE | 116 Participants |
| Bevacizumab Maintenance Trt Arm A | Incidence of Adverse Events and Serious Adverse Event | SAE | 26 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Incidence of Adverse Events and Serious Adverse Event | AE | 123 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Incidence of Adverse Events and Serious Adverse Event | SAE | 42 Participants |
| No Maintenance Trt | Incidence of Adverse Events and Serious Adverse Event | AE | 119 Participants |
| No Maintenance Trt | Incidence of Adverse Events and Serious Adverse Event | SAE | 70 Participants |
Secondary
Number of Participants With Marked Laboratory Abnormalities
Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from Baseline. The reference range for Platelets was 100-550 (10\^9/L), for White blood cells (WBC) was 3.0-18.0 (10\^9/L), for Lymphocytes was 0.70-7.60 (10\^9/L), and Neutrophil 1.50-9.25 (10\^9/L ).
Time frame: Up to 21 months
Population: The safety population comprised of all participants who received at least one dose of study medication. Participants who received induction treatment and were not randomised to maintenance treatment are also included in analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | Platelets | 28 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | International normalized ratio (INR) | 1 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | WBC | 28 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | Neutrophils | 28 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | Lymphocytes | 28 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | Alanine amino transferase (ALT) | 18 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | Alkaline phosphatase | 18 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | Aspartate amino transferase (AST) | 18 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | Serum creatinine | 18 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | Hemoglobin | 28 Participants |
| Bevacizumab Maintenance Trt Arm A | Number of Participants With Marked Laboratory Abnormalities | Activated partial thromboplastin time (aPTT) | 1 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | Lymphocytes | 30 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | Alanine amino transferase (ALT) | 26 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | Aspartate amino transferase (AST) | 26 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | Alkaline phosphatase | 26 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | Hemoglobin | 30 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | International normalized ratio (INR) | 0 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | Neutrophils | 30 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | Platelets | 30 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | Serum creatinine | 26 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | WBC | 30 Participants |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Number of Participants With Marked Laboratory Abnormalities | Activated partial thromboplastin time (aPTT) | 0 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | WBC | 25 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | Platelets | 25 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | Alkaline phosphatase | 8 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | Alanine amino transferase (ALT) | 8 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | Serum creatinine | 8 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | Aspartate amino transferase (AST) | 8 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | Lymphocytes | 25 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | International normalized ratio (INR) | 0 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | Activated partial thromboplastin time (aPTT) | 0 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | Neutrophils | 25 Participants |
| No Maintenance Trt | Number of Participants With Marked Laboratory Abnormalities | Hemoglobin | 25 Participants |
Secondary
Overall Survival During Maintenance Treatment Phase
Overall survival (OS) is assessed from the date of first induction treatment until the date of death. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Population: The ITT population included all the participants that were randomized.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Bevacizumab Maintenance Trt Arm A | Overall Survival During Maintenance Treatment Phase | 15.7 Months |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Overall Survival During Maintenance Treatment Phase | NA Months |
p-value: 0.2395% CI: [0.47, 1.2]Log Rank
Secondary
Quality of Life
European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Cancer 30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Lung Cancer 13 \[EORTC QLQ-LC13\]consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity. QOL was assessed using Pre-Induction Baseline (Pre-ind BL), Maintenance (MTC), End of study (EOS) cycles.
Time frame: Up to 21 months
Population: The ITT population included all the participants that were randomized.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Nausea & Vomiting Scale n=118,121 | 7.2 Score on scale | Standard Deviation 17.5 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Pain Symptom Scale (n=38,64) | 21.5 Score on scale | Standard Deviation 23.86 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Constipation Symptom Scale (n=69,87) | 10.1 Score on scale | Standard Deviation 19.22 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Dyspnea Symptom Scale (n=38,64) | 28.1 Score on scale | Standard Deviation 26.31 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL]Financial Difficulties Scale n=114,120 | 17.3 Score on scale | Standard Deviation 30.48 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Insomnia Symptom Scale (n=38,64) | 16.7 Score on scale | Standard Deviation 26.57 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Diarrhea Symptom Scale (n=69,87) | 3.4 Score on scale | Standard Deviation 12.97 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Appetite Loss Scale (n=38,64) | 12.3 Score on scale | Standard Deviation 21.11 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Cognitive Functional Scale n=117,121 | 86.0 Score on scale | Standard Deviation 21.55 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Constipation Symptom Scale (n=38,64) | 14 Score on scale | Standard Deviation 28.61 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Financial Difficulties Scale (n=68,86 | 18.1 Score on scale | Standard Deviation 27.88 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Diarrhea Symptom Scale (n=38,64) | 8.8 Score on scale | Standard Deviation 20.04 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Global Health Status (n=69,87) | 63.3 Score on scale | Standard Deviation 20.02 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Financial Difficulties Scale n=38,64 | 14.0 Score on scale | Standard Deviation 24.05 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Global Health Status (n=51,77) | 63.2 Score on scale | Standard Deviation 20.36 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Global Health Status Scale (n=33,50) | 60.6 Score on scale | Standard Deviation 18.67 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Pain Symptom Scale (n=118,121) | 36.7 Score on scale | Standard Deviation 31.92 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Physical Functional Scale (n=33,50) | 80.8 Score on scale | Standard Deviation 20.53 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Physical Functional Scale (n=51,77) | 78.7 Score on scale | Standard Deviation 21.29 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Role Functional Scale (n=33,50) | 75.8 Score on scale | Standard Deviation 24.33 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Physical Functional Scale (n=69,87) | 77.1 Score on scale | Standard Deviation 20.72 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Emotional Functional Scale (n=33,50) | 82.3 Score on scale | Standard Deviation 18.61 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Role Functional Scale (n=51,77) | 74.5 Score on scale | Standard Deviation 31.15 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Cognitive Functional Scale (n=33,50) | 83.3 Score on scale | Standard Deviation 20.41 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Physical Functional Scale (n=118,121) | 74.8 Score on scale | Standard Deviation 23.69 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Social Functional Scale (n=33,50) | 83.8 Score on scale | Standard Deviation 24.47 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Emotional Functional Scale (n=51,77) | 78.8 Score on scale | Standard Deviation 23.76 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Fatigue Symptom Scale (n=33,50) | 28.3 Score on scale | Standard Deviation 24.07 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Role Functional Scale (n=69,87) | 74.2 Score on scale | Standard Deviation 27.79 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Nausea & Vomiting Symptom (n=33,50) | 5.1 Score on scale | Standard Deviation 12.14 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Cognitive Functional Scale (n=51,77) | 81.0 Score on scale | Standard Deviation 26.04 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Pain Symptom Scale (n=33,50) | 25.8 Score on scale | Standard Deviation 30.93 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Dyspnea Symptom Scale (n=118,121) | 29.7 Score on scale | Standard Deviation 30.75 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Dyspnea Symptom Scale (n=32,50) | 25.0 Score on scale | Standard Deviation 25.4 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Social Functional Scale (n=51,77) | 85.3 Score on scale | Standard Deviation 22.52 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Insomnia Symptom Scale (n=33,49) | 23.2 Score on scale | Standard Deviation 26.98 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Emotional Functional Scale (n=69,87) | 82.5 Score on scale | Standard Deviation 19.86 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Appetite Loss Scale (n=33,50) | 10.1 Score on scale | Standard Deviation 19.52 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Fatigue Symptom Scale (n=51,77) | 32.2 Score on scale | Standard Deviation 23.01 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Constipation Symptom Scale (n=33,50) | 13.1 Score on scale | Standard Deviation 24.92 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL]] Social Functional Scale (n=116,120) | 79.3 Score on scale | Standard Deviation 25.6 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9 ]Diarrhea Symptom Scale (n=33,50) | 7.1 Score on scale | Standard Deviation 20 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Nausea and Vomiting Scale (n=51,77) | 9.2 Score on scale | Standard Deviation 18.05 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 9]Financial Difficulties Scale n=33,50 | 15.2 Score on scale | Standard Deviation 23.7 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Cognitive Functional Scale (n=69,87) | 84.3 Score on scale | Standard Deviation 23.2 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ] Global Health Status Scale n=25,37 | 57.7 Score on scale | Standard Deviation 18.93 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Pain Symptom Scale (n=51,77) | 23.5 Score on scale | Standard Deviation 26.28 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Physical Functional Scale (n=25,37) | 79.2 Score on scale | Standard Deviation 16.48 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Insomnia Symptom Scale n=118,121 | 33.3 Score on scale | Standard Deviation 34.59 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Role Functional Scale (n=25,37) | 77.3 Score on scale | Standard Deviation 18.56 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Dyspnea Symptom Scale (n=51,77) | 25.5 Score on scale | Standard Deviation 27.96 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Emotional Functional Scale n=25,37 | 78.3 Score on scale | Standard Deviation 19.09 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Social Functional Scale (n=69,87) | 82.1 Score on scale | Standard Deviation 25.62 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Cognitive Functional Scale n=25,37 | 81.3 Score on scale | Standard Deviation 26.49 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Insomnia Symptom Scale( n=51,77) | 21.6 Score on scale | Standard Deviation 28.92 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Social Functional Scale (n=25,37) | 84.7 Score on scale | Standard Deviation 19.2 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Emotional Functional Scale n=117,121 | 71.7 Score on scale | Standard Deviation 21.93 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Fatigue Symptom Scale (n=25,37) | 32.4 Score on scale | Standard Deviation 22.2 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | MTC Cycle 5] Appetite Loss Symptom Scale (n=51,77) | 10.5 Score on scale | Standard Deviation 19.43 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Nausea & Vomiting Scale (n=25,37) | 6.7 Score on scale | Standard Deviation 15.96 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Fatigue Symptom Scale (n=69,87) | 32.1 Score on scale | Standard Deviation 22.88 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Pain Symptom Scale (n=25,37) | 29.3 Score on scale | Standard Deviation 28.98 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Constipation Symptom Scale (n=51,77) | 9.2 Score on scale | Standard Deviation 20.09 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Dyspnea Symptom Scale (n=25,37) | 30.7 Score on scale | Standard Deviation 16.44 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Appetite Loss Symptom Scale n=118,121 | 19.2 Score on scale | Standard Deviation 30.01 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Insomnia Symptom Scale (n=25,37) | 20.0 Score on scale | Standard Deviation 23.57 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Diarrhea Symptom Scale (n=51,77) | 10.5 Score on scale | Standard Deviation 20.54 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Appetite Loss Scale (n=25,37) | 9.3 Score on scale | Standard Deviation 20.46 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Nausea and Vomiting Scale (n=69,87) | 7.2 Score on scale | Standard Deviation 16.78 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | MTC Cycle 11 ]Constipation Symptom Scale( n=25,37) | 6.7 Score on scale | Standard Deviation 13.61 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 5] Financial Difficulties Scale n=50,77 | 16.0 Score on scale | Standard Deviation 28.76 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11 ]Diarrhea Symptom Scale ( n=25,37) | 1.3 Score on scale | Standard Deviation 6.67 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Fatigue Symptom Scale (n=118,121) | 33.3 Score on scale | Standard Deviation 27.18 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 11]Financial Difficulties Scale n=24,37 | 15.3 Score on scale | Standard Deviation 25.97 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7] Global Health Status Scale (n=38,64) | 61.2 Score on scale | Standard Deviation 21.69 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Global Health Status Scale (n=123,127) | 55.1 Score on scale | Standard Deviation 20.62 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Pain Symptom Scale (n=69,87) | 23.9 Score on scale | Standard Deviation 27.64 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Physical Functional Scale (n=125,127) | 70.2 Score on scale | Standard Deviation 23.49 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7] Physical Functional Scale (n=38,64) | 75.6 Score on scale | Standard Deviation 21.49 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Role Functional Scale (n=125,127) | 63.5 Score on scale | Standard Deviation 32.43 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL]] Constipation Symptom Scale n=118,121 | 18.6 Score on scale | Standard Deviation 30.68 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Emotional Functional Scale (n=124,127) | 74.4 Score on scale | Standard Deviation 21.36 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Role Functional Scale (n=38,64) | 76.8 Score on scale | Standard Deviation 24.97 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Cognitive Functional Scale ( n=124,127) | 79.3 Score on scale | Standard Deviation 24.91 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Dyspnea Symptom Scale (n=69,87) | 26.1 Score on scale | Standard Deviation 27.93 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Social Functional Scale (n=124,127) | 73.3 Score on scale | Standard Deviation 29.28 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Emotional Functional Scale (n=38,64) | 81.6 Score on scale | Standard Deviation 22.27 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Fatigue Symptom Scale (n=125,127) | 41.0 Score on scale | Standard Deviation 26.42 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Role Functional Scale (n=118,121) | 68.4 Score on scale | Standard Deviation 32.5 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Nausea & Vomiting Scale (n=125,127) | 14.4 Score on scale | Standard Deviation 23.7 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Cognitive Functional Scale (n=38,64) | 77.2 Score on scale | Standard Deviation 27.51 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Pain Symptom Scale (n=125,127) | 30.4 Score on scale | Standard Deviation 30.31 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | MTC Cycle 3]Appetite Loss Symptom Scale (n=69,87) | 13.5 Score on scale | Standard Deviation 22.37 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Dyspnea Symptom Scale (n=124,127) | 31.5 Score on scale | Standard Deviation 29.85 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Social Functional Scale (n=38,64) | 82.9 Score on scale | Standard Deviation 24.35 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Insomnia Symptom Scale( n=125,127) | 27.2 Score on scale | Standard Deviation 26.57 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Diarrhea Symptom Scale (n=117,121) | 7.1 Score on scale | Standard Deviation 17.96 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Appetite Loss Symptom Scale (n=125,127) | 26.9 Score on scale | Standard Deviation 31.31 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Fatigue Symptom Scale (n=38,64) | 32.3 Score on scale | Standard Deviation 22.07 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Constipation Symptom Scale (n=125,127) | 17.6 Score on scale | Standard Deviation 25.6 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 3]Insomnia Symptom Scale (n=69,87) | 19.3 Score on scale | Standard Deviation 24.53 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Diarrhea Symptom Scale(n=124,127) | 9.7 Score on scale | Standard Deviation 20.72 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [MTC Cycle 7]Nausea & Vomiting Scale (n=38,64) | 8.3 Score on scale | Standard Deviation 18.88 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [EOS]Financial Difficulties Scale (n=123,126) | 16.8 Score on scale | Standard Deviation 27.45 |
| Bevacizumab Maintenance Trt Arm A | Quality of Life | [Pre-ind BL] Global Health Status Scale n=116,121 | 57.9 Score on scale | Standard Deviation 23.9 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Financial Difficulties Scale (n=123,126) | 16.9 Score on scale | Standard Deviation 27.24 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Global Health Status Scale n=116,121 | 59.7 Score on scale | Standard Deviation 21.74 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Physical Functional Scale (n=118,121) | 79.4 Score on scale | Standard Deviation 18.09 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Role Functional Scale (n=118,121) | 71.1 Score on scale | Standard Deviation 28.28 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Emotional Functional Scale n=117,121 | 69.8 Score on scale | Standard Deviation 21.97 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Cognitive Functional Scale n=117,121 | 88.0 Score on scale | Standard Deviation 16.7 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL]] Social Functional Scale (n=116,120) | 78.7 Score on scale | Standard Deviation 26.1 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Fatigue Symptom Scale (n=118,121) | 31.5 Score on scale | Standard Deviation 21.73 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Nausea & Vomiting Scale n=118,121 | 4.3 Score on scale | Standard Deviation 12.46 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Pain Symptom Scale (n=118,121) | 24.7 Score on scale | Standard Deviation 26.88 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Dyspnea Symptom Scale (n=118,121) | 30.6 Score on scale | Standard Deviation 29.69 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Insomnia Symptom Scale n=118,121 | 33.9 Score on scale | Standard Deviation 30.42 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Appetite Loss Symptom Scale n=118,121 | 18.7 Score on scale | Standard Deviation 29.15 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL]] Constipation Symptom Scale n=118,121 | 9.1 Score on scale | Standard Deviation 20.18 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL] Diarrhea Symptom Scale (n=117,121) | 5.2 Score on scale | Standard Deviation 14.91 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [Pre-ind BL]Financial Difficulties Scale n=114,120 | 17.2 Score on scale | Standard Deviation 29.62 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Global Health Status (n=69,87) | 58.6 Score on scale | Standard Deviation 19.71 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Physical Functional Scale (n=69,87) | 76.0 Score on scale | Standard Deviation 20.37 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Role Functional Scale (n=69,87) | 69.9 Score on scale | Standard Deviation 28.51 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Emotional Functional Scale (n=69,87) | 78.4 Score on scale | Standard Deviation 18.48 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Cognitive Functional Scale (n=69,87) | 82.6 Score on scale | Standard Deviation 19.17 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Social Functional Scale (n=69,87) | 73.0 Score on scale | Standard Deviation 24.28 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Fatigue Symptom Scale (n=69,87) | 34.5 Score on scale | Standard Deviation 21.5 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Nausea and Vomiting Scale (n=69,87) | 8.8 Score on scale | Standard Deviation 12.92 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Pain Symptom Scale (n=69,87) | 17.4 Score on scale | Standard Deviation 21.85 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Dyspnea Symptom Scale (n=69,87) | 29.9 Score on scale | Standard Deviation 26.91 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | MTC Cycle 3]Appetite Loss Symptom Scale (n=69,87) | 18.4 Score on scale | Standard Deviation 25.8 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Insomnia Symptom Scale (n=69,87) | 19.5 Score on scale | Standard Deviation 25.19 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Constipation Symptom Scale (n=69,87) | 11.1 Score on scale | Standard Deviation 20.12 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Diarrhea Symptom Scale (n=69,87) | 5.7 Score on scale | Standard Deviation 14.56 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 3]Financial Difficulties Scale (n=68,86 | 19.4 Score on scale | Standard Deviation 26.3 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Global Health Status (n=51,77) | 62.9 Score on scale | Standard Deviation 18.81 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Physical Functional Scale (n=51,77) | 78.4 Score on scale | Standard Deviation 15.45 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Role Functional Scale (n=51,77) | 68.8 Score on scale | Standard Deviation 27.08 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Emotional Functional Scale (n=51,77) | 78.7 Score on scale | Standard Deviation 20.96 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Cognitive Functional Scale (n=51,77) | 84.6 Score on scale | Standard Deviation 18.09 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Social Functional Scale (n=51,77) | 77.9 Score on scale | Standard Deviation 22.85 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Fatigue Symptom Scale (n=51,77) | 34.5 Score on scale | Standard Deviation 22.12 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Nausea and Vomiting Scale (n=51,77) | 10.0 Score on scale | Standard Deviation 20.1 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Pain Symptom Scale (n=51,77) | 20.1 Score on scale | Standard Deviation 25.27 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Dyspnea Symptom Scale (n=51,77) | 35.9 Score on scale | Standard Deviation 30.95 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Insomnia Symptom Scale( n=51,77) | 22.1 Score on scale | Standard Deviation 27.36 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | MTC Cycle 5] Appetite Loss Symptom Scale (n=51,77) | 19.9 Score on scale | Standard Deviation 26.63 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Constipation Symptom Scale (n=51,77) | 17.3 Score on scale | Standard Deviation 29.42 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Diarrhea Symptom Scale (n=51,77) | 2.6 Score on scale | Standard Deviation 8.99 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 5] Financial Difficulties Scale n=50,77 | 17.7 Score on scale | Standard Deviation 23.31 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7] Global Health Status Scale (n=38,64) | 61.3 Score on scale | Standard Deviation 19.55 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7] Physical Functional Scale (n=38,64) | 74.7 Score on scale | Standard Deviation 19.38 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Role Functional Scale (n=38,64) | 70.8 Score on scale | Standard Deviation 28.79 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Emotional Functional Scale (n=38,64) | 77.5 Score on scale | Standard Deviation 18.64 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Cognitive Functional Scale (n=38,64) | 81.0 Score on scale | Standard Deviation 18.98 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Social Functional Scale (n=38,64) | 72.1 Score on scale | Standard Deviation 28.65 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Fatigue Symptom Scale (n=38,64) | 33.7 Score on scale | Standard Deviation 24.72 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Nausea & Vomiting Scale (n=38,64) | 9.6 Score on scale | Standard Deviation 16.48 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Pain Symptom Scale (n=38,64) | 19.8 Score on scale | Standard Deviation 23.55 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Dyspnea Symptom Scale (n=38,64) | 37 Score on scale | Standard Deviation 32.59 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Insomnia Symptom Scale (n=38,64) | 28.6 Score on scale | Standard Deviation 30.21 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Appetite Loss Scale (n=38,64) | 21.4 Score on scale | Standard Deviation 29.32 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Constipation Symptom Scale (n=38,64) | 17.2 Score on scale | Standard Deviation 24.48 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Diarrhea Symptom Scale (n=38,64) | 8.9 Score on scale | Standard Deviation 21.61 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 7]Financial Difficulties Scale n=38,64 | 20.3 Score on scale | Standard Deviation 27.61 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Global Health Status Scale (n=33,50) | 61.2 Score on scale | Standard Deviation 17.71 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Physical Functional Scale (n=33,50) | 74.9 Score on scale | Standard Deviation 19.54 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Role Functional Scale (n=33,50) | 69.7 Score on scale | Standard Deviation 28.51 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Emotional Functional Scale (n=33,50) | 75 Score on scale | Standard Deviation 22.46 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Cognitive Functional Scale (n=33,50) | 81.7 Score on scale | Standard Deviation 19.99 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Social Functional Scale (n=33,50) | 71.7 Score on scale | Standard Deviation 26.78 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Fatigue Symptom Scale (n=33,50) | 35.1 Score on scale | Standard Deviation 25.03 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Nausea & Vomiting Symptom (n=33,50) | 12.0 Score on scale | Standard Deviation 20.77 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Pain Symptom Scale (n=33,50) | 18.7 Score on scale | Standard Deviation 21.47 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Dyspnea Symptom Scale (n=32,50) | 35.3 Score on scale | Standard Deviation 27.28 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Insomnia Symptom Scale (n=33,49) | 30.6 Score on scale | Standard Deviation 33.91 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Appetite Loss Scale (n=33,50) | 23.3 Score on scale | Standard Deviation 29.55 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Constipation Symptom Scale (n=33,50) | 16.0 Score on scale | Standard Deviation 25.41 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9 ]Diarrhea Symptom Scale (n=33,50) | 7.3 Score on scale | Standard Deviation 18.18 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 9]Financial Difficulties Scale n=33,50 | 22.0 Score on scale | Standard Deviation 27.45 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ] Global Health Status Scale n=25,37 | 59.9 Score on scale | Standard Deviation 21.41 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Physical Functional Scale (n=25,37) | 81.1 Score on scale | Standard Deviation 17.81 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Role Functional Scale (n=25,37) | 73.9 Score on scale | Standard Deviation 27.37 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Emotional Functional Scale n=25,37 | 80.0 Score on scale | Standard Deviation 19.88 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Cognitive Functional Scale n=25,37 | 84.2 Score on scale | Standard Deviation 17.1 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Social Functional Scale (n=25,37) | 77.9 Score on scale | Standard Deviation 27.51 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Fatigue Symptom Scale (n=25,37) | 31.2 Score on scale | Standard Deviation 20.92 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Nausea & Vomiting Scale (n=25,37) | 9.5 Score on scale | Standard Deviation 18.23 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Pain Symptom Scale (n=25,37) | 19.8 Score on scale | Standard Deviation 27.45 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Dyspnea Symptom Scale (n=25,37) | 28.8 Score on scale | Standard Deviation 27.4 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Insomnia Symptom Scale (n=25,37) | 18.9 Score on scale | Standard Deviation 26.69 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Appetite Loss Scale (n=25,37) | 18 Score on scale | Standard Deviation 26.75 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | MTC Cycle 11 ]Constipation Symptom Scale( n=25,37) | 17.1 Score on scale | Standard Deviation 24.37 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11 ]Diarrhea Symptom Scale ( n=25,37) | 7.2 Score on scale | Standard Deviation 15.98 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [MTC Cycle 11]Financial Difficulties Scale n=24,37 | 18.0 Score on scale | Standard Deviation 26.75 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Global Health Status Scale (n=123,127) | 57.2 Score on scale | Standard Deviation 20.01 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Physical Functional Scale (n=125,127) | 72.5 Score on scale | Standard Deviation 22.06 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Role Functional Scale (n=125,127) | 64.3 Score on scale | Standard Deviation 29.68 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Emotional Functional Scale (n=124,127) | 77.3 Score on scale | Standard Deviation 20.2 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Cognitive Functional Scale ( n=124,127) | 83.5 Score on scale | Standard Deviation 19.3 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Social Functional Scale (n=124,127) | 72.6 Score on scale | Standard Deviation 27.9 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Fatigue Symptom Scale (n=125,127) | 37.6 Score on scale | Standard Deviation 23.8 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Nausea & Vomiting Scale (n=125,127) | 12.3 Score on scale | Standard Deviation 20.7 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Pain Symptom Scale (n=125,127) | 21.1 Score on scale | Standard Deviation 25.58 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Dyspnea Symptom Scale (n=124,127) | 34.1 Score on scale | Standard Deviation 29.83 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Insomnia Symptom Scale( n=125,127) | 22.6 Score on scale | Standard Deviation 28.45 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Appetite Loss Symptom Scale (n=125,127) | 26.0 Score on scale | Standard Deviation 30.26 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Constipation Symptom Scale (n=125,127) | 12.1 Score on scale | Standard Deviation 21.28 |
| Bevacizumab +Pemetrexed Maintenance Trt Arm B | Quality of Life | [EOS]Diarrhea Symptom Scale(n=124,127) | 6.8 Score on scale | Standard Deviation 15.34 |